Company intelligence / Profile preview
Abcuro
Newton, Massachusetts, United Statesabcuro.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Abcuro’s lead candidate ABC008, an anti-KLRG1 monoclonal antibody, has shown potent depletion of highly cytotoxic T cells in early clinical trials. Initial results from the Phase 1 trial in inclusion body myositis demonstrated safety and pharmacodynamic activity. The company has advanced to a registrational Phase 2/3 trial in IBM and a Phase 1/2 trial in T-LGLL. Orphan drug designation was granted by both FDA and EMA for IBM. The approach aims to treat autoimmune diseases and rare cancers by selectively targeting pathogenic immune cells while sparing beneficial ones.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- monoclonal antibodies (mAbs)immunotherapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed; investors include Sanofi Ventures which may indicate some relationship.
Beyond the preview
Go deeper on Abcuro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abcuro.